Compounds for Modulation of Alpha-Ketoglutaric Acid Dependent Oxygenases
Summary
The European Patent Office published patent application EP3762038A1 for therapeutic compounds designed to modulate alpha-ketoglutaric acid (2OG)-dependent oxygenases for anti-neoplastic applications. The applicant and inventor is Thomas Melchior Homann. The patent covers designated states across the EU member states including DE, FR, GB, IT, ES, NL, and others.
What changed
The EPO published patent EP3762038A1 on March 25, 2026, covering compounds for modulation and functional replacement of alpha-ketoglutaric acid (2OG)-dependent oxygenases for therapeutic use. The patent is classified under A61K 31/194, A61K 47/54, A61K 47/64, C12N 9/99, and A61P 35/00 (anti-neoplastic agents). Designated contracting states include all EU member states plus additional European countries.
This patent publication establishes intellectual property rights for the disclosed compounds and their therapeutic applications. No immediate compliance actions are required from pharmaceutical companies or healthcare providers. Entities developing 2OG-dependent oxygenase modulators should evaluate potential patent overlap with EP3762038A1 before proceeding with research or commercialization activities.
Archived snapshot
Apr 1, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUNDS FOR MODULATION AND AS FUNCTIONAL REPLACEMENT OF ALPHA-KETOGLUTARIC ACID (2OG)-DEPENDENT OXYGENASES
Publication EP3762038A1 Kind: A1 Mar 25, 2026
Applicants
Homann, Thomas Melchior
Inventors
Homann, Thomas Melchior
IPC Classifications
A61K 31/194 20060101AFI20250604BHEP A61K 47/54 20170101ALI20250604BHEP A61K 47/64 20170101ALI20250604BHEP C12N 9/99 20060101ALI20250604BHEP A61P 35/00 20060101ALI20250604BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.